This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00669806%3A_____%2F13%3A10140091%21RIV14-MZ0-00669806/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00669806%3A_____%2F13%3A10140091%21RIV14-MZ0-00669806
rdf:type
skos:Concept n9:Vysledek
rdfs:seeAlso
http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=3407&category_id=102&option=com_virtuemart&vmcchk=1&Itemid=1
dcterms:description
Molecular targeted therapy based on EGFR tyrosine kinase inhibitors (EGFR-TKI) is currently astate of the art option for management of advanced stage NSCLC. Activating EGFR mutations are preferable for a good treatment response to EGFR-TKI. The presented retrospective study evaluated a clinical observation of EGFR-TKI aiming at its efficacy and safety in comparison to a standard chemotherapy in the first-line treatment of advanced stage NSCLC. Total number of patients with advanced stage (IIIB, IV) EGFR mutation-positive NSCLC was 54 of which 23 were treated with EGFR-TKI and 31 patients with various chemotherapy regimens in the first line. The treatment efficacy was characterized in terms of disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). The comparison of DCR was performed using Fisher's exact test and the differences in survival were tested using log-rank test. DCR for EGFR-TKI treatment was 95.6% vs. 70.9% for chemotherapy (p=0.032). Median of PFS in patients treated with EGFR-TKI was 7.2 months vs. 2.5 months in patients treated with chemotherapy (p<0.001). Median of OS was 14.5 months vs. 21.4 months (p=0.729). EGFR-TKI was associated with higher incidence of skin rash and diarrhoea; chemotherapy was associated with higher incidence of haematologic adverse events and nausea or vomiting. The analysis results showed a favourable DCR and PFS in patients treated with EGFR-TKI in the first line. The non-significant difference in OS could be attributed to a cross-over during the patient follow-up as well as the differences in performance status and age between both groups. EGFR-TKI is the optimal choice for the first-line treatment of EGFR mutation-positive NSCLC. Molecular targeted therapy based on EGFR tyrosine kinase inhibitors (EGFR-TKI) is currently astate of the art option for management of advanced stage NSCLC. Activating EGFR mutations are preferable for a good treatment response to EGFR-TKI. The presented retrospective study evaluated a clinical observation of EGFR-TKI aiming at its efficacy and safety in comparison to a standard chemotherapy in the first-line treatment of advanced stage NSCLC. Total number of patients with advanced stage (IIIB, IV) EGFR mutation-positive NSCLC was 54 of which 23 were treated with EGFR-TKI and 31 patients with various chemotherapy regimens in the first line. The treatment efficacy was characterized in terms of disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). The comparison of DCR was performed using Fisher's exact test and the differences in survival were tested using log-rank test. DCR for EGFR-TKI treatment was 95.6% vs. 70.9% for chemotherapy (p=0.032). Median of PFS in patients treated with EGFR-TKI was 7.2 months vs. 2.5 months in patients treated with chemotherapy (p<0.001). Median of OS was 14.5 months vs. 21.4 months (p=0.729). EGFR-TKI was associated with higher incidence of skin rash and diarrhoea; chemotherapy was associated with higher incidence of haematologic adverse events and nausea or vomiting. The analysis results showed a favourable DCR and PFS in patients treated with EGFR-TKI in the first line. The non-significant difference in OS could be attributed to a cross-over during the patient follow-up as well as the differences in performance status and age between both groups. EGFR-TKI is the optimal choice for the first-line treatment of EGFR mutation-positive NSCLC.
dcterms:title
Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
skos:prefLabel
Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
skos:notation
RIV/00669806:_____/13:10140091!RIV14-MZ0-00669806
n9:predkladatel
n10:ico%3A00669806
n4:aktivita
n11:P n11:I
n4:aktivity
I, P(NR9087)
n4:cisloPeriodika
4
n4:dodaniDat
n15:2014
n4:domaciTvurceVysledku
n13:9221670 n13:1821407 n13:4249844
n4:druhVysledku
n5:J
n4:duvernostUdaju
n16:S
n4:entitaPredkladatele
n8:predkladatel
n4:idSjednocenehoVysledku
66191
n4:idVysledku
RIV/00669806:_____/13:10140091
n4:jazykVysledku
n19:eng
n4:klicovaSlova
targeted treatment of NSCLC; gefitinib; erlotinib; NSCLC; first-line treatment; EGFR-TKI
n4:klicoveSlovo
n7:erlotinib n7:NSCLC n7:EGFR-TKI n7:first-line%20treatment n7:gefitinib n7:targeted%20treatment%20of%20NSCLC
n4:kodStatuVydavatele
SK - Slovenská republika
n4:kontrolniKodProRIV
[78C0D2C63407]
n4:nazevZdroje
Neoplasma
n4:obor
n20:FD
n4:pocetDomacichTvurcuVysledku
3
n4:pocetTvurcuVysledku
6
n4:projekt
n18:NR9087
n4:rokUplatneniVysledku
n15:2013
n4:svazekPeriodika
60
n4:tvurceVysledku
Fínek, Jindřich Bortlíček, Zdeněk Benešová, Lucie Minárik, Marek Fiala, Ondřej Pešek, Miloš
n4:wos
000319535400010
s:issn
0028-2685
s:numberOfPages
7
n17:doi
10.4149/neo_2013_055